Lupin gets USFDA nod to market generic anti-bacterial drug

Drug maker Lupin today said it has received US health regulator's nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.

Published: 13th September 2017 04:38 PM  |   Last Updated: 13th September 2017 04:38 PM   |  A+A-

An employee of Lupin Limited works at a reception at their headquarters in Mumbai. (File Photo | Reuters)

By PTI

NEW DELHI: Drug maker Lupin today said it has received US health regulator's nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.

The company has received final approval from the US Food and Drug Administration (US FDA) to market metronidazole tablets in strengths of 250 mg and 500 mg, Lupin said in a statement.

The Mumbai-based company's product is a generic version of G D Searle LLC's Flagyl tablets which are indicated in the treatment of a wide variety of bacterial infections.

As per IMS MAT sales June data, Flagyl tablets had sales of USD 44.1 million in the US market.

Lupin shares today closed 1.39 per cent up at Rs 995 per scrip on BSE.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL2018